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Background: Metoclopramide use is associated with serious and potentially irreversible 
neurologic side effects. However, it is often used for questionable or unclear indications in 
clinical practice.
Objectives: To (1) determine whether an intervention targeted at the prescribing physi-
cian would increase the rate of metoclopramide discontinuation among patients prescribed 
the medication for questionable or unclear indications; and (2) assess the durability of the 
discontinuation.
Study design: A randomized controlled trial.
Setting: Ambulatory practices of a quaternary care medical center.
Participants: Ambulatory, electronic medical record-utilizing clinicians of the quaternary 
medical center.
Intervention: A letter regarding participating clinicians’ prescription(s) of metoclopramide 
for patients with questionable or unclear indications.
Main outcome measures: The rate and the durability of metoclopramide discontinuation.
Results: Fourteen of 31 (45%) patients of intervention group clinicians and 10 of 30 (33%) 
patients of nonintervention group clinicians had metoclopramide discontinued within 12 weeks, 
yielding a risk ratio for metoclopramide discontinuation of 1.4 (95% confidence interval 
[CI] 0.6–3.0) in the intervention versus nonintervention group. Of the 29 patients who had 
their metoclopramide discontinued during the study, 26 (90%, 95% CI 73%–98%) still had 
no active metoclopramide prescription in the subsequent 6 months. No adverse events were 
detected during the follow-up period.
Conclusion: A physician-targeted intervention letter did not lead to a statistically significantly 
increased rate of metoclopramide discontinuation among patients who had questionable or 
unclear indications for the medication. Discontinuation of metoclopramide therapy for ques-
tionable or unclear indications was durable in most patients.
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Introduction
Metoclopramide is a 5-hydroxytryptamine (5-HT)4 agonist, dopaminergic, and 5-HT3 
antagonist. It is commonly used as a pro-motility agent. The antidopamine receptor 
effect of metoclopramide can lead to extrapyramidal symptoms such as dystonia, akath-
isia, and tardive dyskinesia.1 Tardive dyskinesia is a potentially irreversible disfiguring 
movement disorder. Its prevalence among patients receiving chronic metoclopramide 
therapy has been reported to be as high as 29%.1 In fact, metoclopramide has been 
regarded by some to be the most common cause of tardive dyskinesia.2 Long-term 
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factors for metoclopramide-induced tardive dyskinesia.2 In 
February 2009, the US Food and Drug Administration (FDA) 
required the manufacturers of metoclopramide to add a box 
warning about these risks and implement a risk evaluation 
and mitigation strategy. (http://www.fda.gov/newsevents/
newsroom/pressannouncements/ucm149533.htm.)
Furthermore, a recent analysis conducted by the FDA 
revealed that a substantial proportion of metoclopramide 
users are being prescribed the medication for longer than the 
12-week maximum duration recommended by the drug label.3 
Furthermore, many patients are receiving metoclopramide 
for unproven indications in practice. For example, a recent 
query of an outpatient electronic medical database system 
at our institution showed that from 1998 to 2003, use of 
metoclopramide had doubled, long-term use was prevalent, 
and over 33% of recipients were prescribed the medica-
tion for unspecified or questionable indications (gastritis, 
constipation, abdominal pain, or esophageal dysmotility) 
(unpublished data). In fact, 50% of prescriptions for question-
able indications were for chronic therapy (ie, $12 weeks). 
In addition, 17% of patients received metoclopramide for 
treatment of gastroesophageal reflux disease (GERD) in the 
absence of documented gastroparesis, a situation in which 
risk greatly outweighs benefit in the light of a proton pump 
inhibitor as a therapeutic alternative. Furthermore, a discus-
sion of the potential side effects of metoclopramide was 
documented in the electronic charts of only 6% of persons 
on chronic metoclopramide therapy. These results suggest 
that a significant number of patients may be receiving chronic 
metoclopramide therapy with only an assumption of benefit, 
and therefore, may safely discontinue this potentially harm-
ful medication.
Recent evidence suggests that a properly designed 
  physician feedback intervention may be effective in chang-
ing physician prescribing practices.4 Essential elements of 
such a feedback should include: the identities of the inap-
propriately treated patients, detailed information regarding 
the prescription event in question, basis for the recommen-
dations (ie, expert opinion, specific clinical evidence with 
references), and preservation of physician autonomy.4 Given 
the well known risk of tardive dyskinesia associated with 
metoclopramide and the high prevalence of potentially inap-
propriate prescribing of metoclopramide in our institution, 
we sought to evaluate whether a physician-targeted feedback 
intervention that included these essential elements resulted 
in more patients undergoing a trial of discontinuation of 
metoclopramide therapy. We also evaluated the long-term 
success rate (ie, durability) of this discontinuation trial.
Methods
general study design
The primary design of the study was a randomized controlled 
trial (ClinicalTrials.gov Identifier: NCT01126034) conducted 
at the prescribing physician level to assess the efficacy 
of a physician-targeted intervention, as determined by a 
patient’s metoclopramide discontinuation within 6 weeks. 
Subsequently, clinicians initially assigned to receive no inter-
vention were crossed-over to the intervention arm. Among 
all patients whose metoclopramide was discontinued, the 
durability of the discontinuation was assessed in a 6-month 
secondary follow-up period. The Institutional Review Board 
at the University of Pennsylvania approved the study along 
with waivers of informed consent and Health Insurance 
Portability and Accountability Act authorization.
Data source
Clinical Practices of the University of Pennsylvania (CPUP) 
are the physician-faculty practices of the University of 
  Pennsylvania Health System, comprising approximately 
725 primary care and specialty physicians, physician assis-
tants, and advance practice nurses. EpicCare is the outpatient 
electronic medical record system used principally by CPUP 
practices. It captures all clinical notes for outpatient visits as 
well as phone calls and other orders that take place outside the 
context of a visit. Much of the detail of the note is recorded 
as unstructured text (ie, free text), though many important 
  elements, such as diagnoses, prescription information, labo-
ratory data, and radiology studies, are recorded as discrete, 
  queriable fields. Additionally, EpicCare practitioners utilize 
this electronic medical record system to generate prescriptions. 
Therefore, it captures all medications ordered, along with dose 
instructions, dispense amount, and numbers of refills.
study population
We included as potential study subjects all CPUP physicians, 
staff physician assistants, and staff certified registered nurse 
practitioners who prescribed medications and used EpicCare 
in their outpatient clinics as of March 2007. We excluded 
all physicians-in-training (ie, residents and fellows) and 
investigators of the current study.
Randomization
We first randomized all eligible CPUP physicians (n = 652) 
to either intervention or nonintervention status at a 1:1 
ratio. The EpicCare database was then queried to identify 
all eligible physicians who were the ordering physician for 
at least one active prescription order for metoclopramide in Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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EpicCare as of March 1, 2007. A prescription was considered 
active if the date of the last prescription before March 1, 
2007 plus the intended duration of therapy of that prescrip-
tion (including refills) was later than 30 days before March 
1, 2007.   Forty-four prescribers were identified, involving 
85 physician-patient pairs. The EpicCare electronic medical 
records of all patients involved were then manually reviewed 
by a gastroenterologist (Y-X Y) to determine the indications 
for the metoclopramide prescriptions. The indications were 
determined by searching for the relevant diagnoses using 
International Classification of Diseases, Revision 9, codes 
and by manually reviewing clinician notes for all documented 
encounters. We defined questionable indications as: gastritis, 
constipation, abdominal pain, esophageal dysmotility, and 
GERD without documented gastroparesis. Patients who 
  carried a diagnosis of gastroparesis or had a gastric emptying 
study documenting delayed gastric emptying were excluded 
from further analysis, as were pregnant patients who received 
metoclopramide for pregnancy related nausea and   vomiting. 
Of the 652 eligible physicians randomized, only those who 
ordered an active metoclopramide prescription with a ques-
tionable indication (n = 38) eventually composed of the two 
comparison groups based on their original randomization 
assignment. The intervention group ultimately included 
18 physicians and 31 patients; the nonintervention group 
included 20 physicians and 30 patients (Figure 1).
intervention
Physicians in the intervention group were mailed a written 
feedback letter regarding their patients who were prescribed 
questionable metoclopramide therapy. Nonintervention 
providers received no letter. Since the randomization and 
intervention took place at the level of the ordering physi-
cians, once a physician was assigned to the intervention 
group, he/she may have received multiple episodes of the 
intervention with reference to different patients if he/she 
prescribed metoclopramide with questionable indications 
for multiple patients. The letter consisted of the following 
components:
•	 The name and medical record number of the patient(s) 
involved
•	 Information regarding the metoclopramide prescription: 
dates, dosage, indication recorded, and the duration of 
therapy
•	 A reminder of the adverse effects of long-term metoclo-
pramide therapy
•	 A recommendation to consider having the patient undergo 
a trial of metoclopramide discontinuation if   appropriate, 
and chart documentation of a discussion of risk and 
  benefits of metoclopramide therapy with patients
•	 A request that the physician document the discontinuation 
trial in the electronic medical record.
Outcomes measured
Twelve weeks after the intervention period, we searched the 
electronic medical records of patients in the intervention and 
nonintervention groups to determine whether discontinuation 
of metoclopramide therapy had taken place. Discontinuation 
status was defined as an EpicCare note documenting a trial of 
discontinuation based on record review (Y-X Y), or absence 
of any active metoclopramide prescription by the 84th day 
post-intervention (ie, 12 weeks).
Administration of the intervention to the 
nonintervention group (crossover phase)
Following the 12 weeks after the intervention letters were sent 
to the intervention group, the physicians in the noninterven-
tion group who still had a patient on active metoclopramide 
therapy at that point were sent the same intervention letter. 
Another 12 weeks later, we searched the medical record to 
determine the rate of discontinuation of metoclopramide 
therapy among those who were in the original noninterven-
tion group and received the intervention letter during the 
crossover stage.
Assessment of durability  
of metoclopramide discontinuation
For all patients whose metoclopramide was discontinued 
in either the initial phase or the crossover phase, their 
entire electronic medical records for the first 6 months 
  following the discontinuation were manually reviewed by 
the   gastroenterologist (Y-X Y) to determine whether they 
had an active prescription for metoclopramide during that 
period. A   successful trial of metoclopramide discontinuation 
was defined as no prescription of metoclopramide during the 
6 months following the initial discontinuation of therapy.
statistical analysis
We used descriptive statistics to compare the characteristics 
of the providers and patients between the intervention and 
nonintervention groups. For the randomized controlled trial, 
comparison of the rates of patients entering a metoclopramide 
discontinuation trial between the intervention and nonin-
tervention groups was performed. In order to account for 
clustering by physician, our primary analysis was performed 
using a generalized estimation equation (GEE) model to Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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estimate risk ratio. The rate and 95% confidence interval (CI) 
of 6-month persistent discontinuation were determined. All 
analyses were performed according to the intention-to-treat 
principle. Stata 8.0. (StataCorp LP, College Station, TX) was 
used for all analyses.
Results
The characteristics of the providers and patients in the inter-
vention and nonintervention arms are compared in Table 1. 
Providers and patients in both arms were similar with respect 
to distribution of physician specialty, sex, age, and apparent 
indications for metoclopramide.
Among intervention group providers, 14 of 31 (45%) 
patients had metoclopramide discontinued at 12 weeks 
post-intervention. In comparison, 10 of 30 (33%) patients of 
nonintervention providers had metoclopramide discontinued 
at the same time point. The slightly higher rate of discontinu-
ation in the intervention group did not meet the threshold for 
statistical significance. The risk ratio for metoclopramide 
discontinuation (ie, having no active metoclopramide 
All CPUP physicians
1:1 Randomization
Identify provider-patient pairs
with metoclopramide
prescriptions
Intervention group
(No. of patients
involved = 45)
Nonintervention group
(No. of patients
involved = 40)
Chart review to apply
exclusion criteria
(14 excluded)
Chart review to apply
exclusion criteria
(10 excluded)
No intervention
applied to 20
providers
(No. of patients
involved = 30)
12 weeks
6 months
12 weeks
6 months 6 months
12 weeks
Intervention applied to
18 providers
(No. of patients
involved = 31)
Patients with
metoclopramide
discontinued
(N = 14)
Patients remained on
metoclopramide
(N = 20)
Patients with
metoclopramide
discontinued
(N =10)
Intervention applied
Patients with
metoclopramide
discontinued
(N = 5)
Patients remained off
metoclopramide
(N = 9)
Patients remained off
 metoclopramide
(N = 4)
Patients remained off
metoclopramide
(N = 13)
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Table  1  Comparisons  of  the  providers  and  patients  in  the 
intervention and nonintervention groupsa
Providers in  
intervention  
group
(N = 18)
Providers in  
nonintervention   
group
(N = 20)
specialties
    general internal  
medicine/primary care
13 12
  nephrology 2 2
  endocrine/diabetes clinic 2 1
  gastroenterology 0 2
  geriatrics 1 1
  Cardiology 0 2
    Median number  
of patients  
per provider (range)
1 (1–8) 1 (1–3)
Patients in  
intervention  
group
(N = 31)
Patients in  
nonintervention   
group
(N = 30)
Female sex 20 (65%) 18 (60%)
Mean age  
(standard deviation)
59 (16) 55 (19)
indication for  
metoclopramide
  Unknown 13 14
  geRD 14 12
  nausea/vomiting 2 2
  epigastric pain 1 1
  Dysphagia 1 0
Note: aP . 0.05 for all comparisons.
Abbreviation: GERD, gastroesophageal reflux disease.
Table 2 Comparison of the intervention and nonintervention groups with regard to rate of metoclopramide discontinuation during 
the randomized trial and persistence of discontinuation
Patients in  
intervention arm
(N = 31)
Patients in  
nonintervention arm
(N = 30)
Risk ratio (95% CI)
number of patients with metoclopramide  
discontinued at the end of 12-week randomized  
trial (%)
14 (45%) 10 (33%) 1.4 (0.6–3.0)
number of patients remained off  
metoclopramide during the next 6 months
13 9 nA
Abbreviations: CI, confidence interval; NA, not applicable.
prescription by the 12-week time point) associated with 
receiving the intervention versus not receiving the interven-
tion was 1.4 (95% CI 0.6–3.0). Among the 24 patients who 
had metoclopramide therapy discontinued by the end of the 
randomized trial phase either spontaneously or following the 
intervention, 22 (92%; 95% CI 73%–99%) remained without 
an active metoclopramide prescription in the subsequent 
6 months (Table 2).
Twenty of the 30 patients in the nonintervention group 
still had an active metoclopramide prescription at the end 
of the randomized trial phase (Table 3). According to our 
protocol, the physicians of all these 20 patients received the 
intervention letter at the end of the randomized trial phase. Of 
these, five (25%) had metoclopramide discontinued 12 weeks 
after the intervention, and four of the five patients still had 
no active metoclopramide prescription after an additional 
6 months of follow-up.
Overall, among the 29 metoclopramide users from either 
the intervention or nonintervention groups whose metoclo-
pramide was discontinued during the entire study period, 
26 (90%; 95% CI 73%–98%) still did not have an active 
metoclopramide prescription 6 months later. No adverse 
events as a result of the discontinuation were detected dur-
ing the follow-up period among these patients based on 
electronic chart review.
Discussion
In this single-center randomized controlled trial, we found 
that a physician-targeted intervention letter led to a statisti-
cally nonsignificant increase in the rate of metoclopramide 
discontinuation among patients who had unspecified or 
questionable indications for metoclopramide. In addition, 
a metoclopramide discontinuation trial appeared safe and 
feasible in a large proportion of this selected population of 
metoclopramide users. Finally, the vast majority of those who 
enter the discontinuation trial remained off metoclopramide 
in the long term.
Metoclopramide can induce tardive dyskinesia, an irre-
versible movement disorder. Existing data suggest that the 
tardive dyskinesia mostly occur after prolonged exposure 
and high cumulative exposure.2 The metoclopramide drug 
label recommends against duration of therapy longer than 
12 weeks, but off-label and long-term use of metoclopramide 
is prevalent in practice.3 In addition, there is no evidence to 
support the use of metoclopramide in gastritis, constipation, 
abdominal pain, or esophageal dysmotility. Furthermore, acid 
reflux disease can be managed with safer and more effec-
tive treatment alternatives in patients without documented Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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delayed gastric emptying. Previous clinical trials have 
demonstrated the superiority of the proton pump inhibitors 
(PPIs) over metoclopramide monotherapy or metoclopramide 
in combination with a histamine 2 receptor antagonist in the 
treatment of GERD.5 In fact, because PPIs are such potent 
acid suppressants and highly effective in true GERD patients, 
most patients with persistent GERD-like symptoms not 
responding to PPI therapy likely have alternative explana-
tions for their symptoms. In a minority of patients who truly 
have residual GERD symptoms after twice daily PPI therapy 
and evidence of delayed gastric emptying, a brief trial of 
metoclopramide therapy in addition to the PPI therapy might 
be considered. However, even this practice is not supported 
by conclusive evidence. Our results confirmed our suspicion 
that a significant proportion of patients with questionable 
indications for metoclopramide therapy can safely be taken 
off this medication, suggesting that they were not likely 
benefiting from the medication in the first place.
There are a wide range of interventions for improving 
physician practice. These mainly include auditing, feedbacks, 
reminders, opinion leaders, printed educational material, 
continuing medical education activities, educational outreach 
visits, patient mediated interventions, and local consensus 
processes.6 Many of these interventions have no effect based 
on large systematic reviews.7–10 Some of these methods such 
as auditing and feedback have shown some success, but none 
was effective in all situations.8,11 While a large systematic 
review concluded that physician feedback can improve 
physician practice, in particular prescribing,12 several previ-
ous randomized controlled studies found that an unsolicited 
written physician feedback system had a minimal effect 
on prescribing practices.4,13,14 Consistent with these data, 
our intervention letter, which contained all of the elements 
purported to be essential for effective physician feedback,4 
also failed to lead to a statistically significant improvement 
in metoclopramide prescribing practices.
Our study has several important limitations. First the 
single-center nature limits its generalizability. Second, we 
may have been under-powered to detect a beneficial effect of 
the intervention letter. Third, our 6-month follow-up period 
may be too short to determine the long-term durability of 
the metoclopramide discontinuation. Fourth, there may be a 
potential clustering effect among physicians from the same 
practice (eg, they may be more likely to have similar prescrib-
ing habits), which might bias the results. However, we used 
GEE modeling in our analysis to account for this potential 
clustering effect. Finally, we used presence or absence of an 
active prescription in our medical records as a surrogate for 
actual metoclopramide use. This may have overestimated the 
rate of metoclopramide use among those who did not comply 
with the prescription. On the other hand, we might have under-
estimated metoclopramide use among patients who get their 
prescription from sources outside of our health system.
In summary, in this single-center randomized controlled 
trial, we revealed that a physician-targeted intervention letter 
to reduce inappropriate metoclopramide therapy might not 
be a very effective quality improvement intervention in a set-
ting similar to ours. That being said, once patients receiving 
such therapy have it discontinued, they tend to remain off 
the drug at least over the next 6 months.
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